CRISPR Therapeutics AG Stock News

Cathie Wood, the chief executive officer of Ark Invest, can be somewhat of a polarizing figure, with some research indicating that her investment firm's actively managed exchange-traded funds (ETFs) have significantly destroyed shareholder value over the long run. Even if that's the case, let's give credit where credit is due.

Investing in modestly sized growth stocks can lead to significant returns, but oftentimes it requires taking on a fair bit of risk and being willing to wait at least a few years for a payoff. There are, however, ways to reduce your risk, such as by targeting stocks with good financials and that already have approved products with a lot of potential.

Most investors probably step into a stock with the intent of holding on to it indefinitely (as long as nothing significant changes, and it continues to perform well). Sometimes, though, new technologies put a company and its stock in a position to shine brilliantly for only a few years.

Healthcare stocks have struggled since interest rates began climbing in 2022. Rising yields pulled capital away from speculative biotech and drug development, pushing valuations lower even as research pipelines advanced.

-Preclinical data presented at the European Society of Gene and Cell Therapy (ESGCT) highlight a potential best-in-class profile-

On Sept. 30, Pfizer announced a deal with the U.S. government that will allow the pharmaceutical leader to avoid President Donald Trump's tariffs for three years in exchange for slashing the prices of certain drugs in the U.S. and investing in local manufacturing efforts. This deal lifted not only Pfizer, but also much of the healthcare sector, especially the company's drugmaking peers, as Wall...

ZUG, Switzerland and BOSTON, Oct. 01, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the acceptance of an abstract for oral presentation at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress, taking place October 7-10, 2025. The presenta...

You don't have to invest a fortune to get involved in an industry that could offer your portfolio growth along with safety. I'm talking about the field of healthcare, specifically companies that develop therapeutics.